Navigation Links
Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
Date:8/8/2011

continuing the dispute resolution process because we strongly believe that there is a patient population for Contrave that has a risk:benefit profile that justifies approval without results from a cardiovascular outcomes trial," stated Mike Narachi, Orexigen President and CEO.  "Importantly, we have prioritized the pursuit of additional assets and are optimistic in these business development efforts."  

About Orexigen TherapeuticsWe are a biopharmaceutical company focused on expanding our pipeline of product candidates through one or more in-license, asset acquisitions or merger transactions where we can leverage our management team, cash and other resources.  Our strategy stems from feedback received from the U.S. Food and Drug Administration, or FDA, concerning substantial additional development requirements for our lead product candidate, Contrave.  Contrave has completed Phase III clinical trials, and our other product candidate, Empatic™, has completed Phase II clinical trials.  Each of the components of our product candidates has already received regulatory approval and has been commercialized previously.  We are appealing the FDA's additional development requirements for Contrave through the formal dispute resolution process. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements  Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding substantially lower c
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, announced today that ... to support a strong launch of Edwards Lifesciences Foundation,s ... to improve the global communities where its employees live ... corporate giving will exceed $8 million, including more than ...
(Date:11/21/2014)... 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or ... Todd Martensen has been ... role of Chief Commercial Officer, to oversee KLOX,s commercial ... gel for the treatment of chronic and other hard-to-heal ... approved in Europe . Mr. Martensen, ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. ... first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud ... INVAP to design its Medical Isotope Production ... Mo-99 is the parent isotope of Technetium-99, which is ... In 2012, Congress passed legislation making it a national ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... , ABBOTT PARK, Ill., Dec. 2 Abbott,s Ibis technology ... named one of the top innovations in 2009 by The ... broad range of life science technologies to determine the year,s top ... online at www.the-scien t ist.com/top10innovations . ...
... , NEW YORK, Dec. 2 ... veteran attorneys, led by Neil H. Ekblom, LeClairRyan,s medical ... the New York market. Mr. Ekblom, a former state ... , The New York team adds to an existing ...
Cached Medicine Technology:Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 3
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 ... for the dental practice. It includes everything needed to ... , Procedure Coding with CDT , CDT 2015 codes ... from January 1, 2014 - December 31, 2014. Dental ... procedures and services on dental claims. There are significant ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... 2014 M3 Global Research , a ... panel, today announced two important leadership changes to help accelerate ... President of Market Research, Americas and the promotion of Anton ... , Ms. DasGupta joined M3 in 2011 and has held ... of Sales. Roni has over 17 years of experience ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... the wall of a still-beating heart has the potential to ... to a new study. Heart patients who received the ... to walk hundreds of feet farther during a six-minute walk ... of the cardiovascular division at Washington University School of Medicine ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... Health experts have warned that the growing menace of ... contained// otherwise there would be a global health crisis. ... safety in the developed and developing world," said Jo ... the low penalties for counterfeits are shocking. Countering supply ...
... which they say can be controlled by the power ... Kamitani and colleagues, mimics the movements of a person's ... (fMRI) of their brain activity, reported the online edition ... Computational Neuroscience Laboratories in Kyoto and from the Honda ...
... the San Francisco VA Medical Center and the University of California, San Francisco, poor literacy ... two times as likely to have poor health and poor health care access in people ... ... Elders with limited literacy, which the researchers define ...
... was suspended a she removed the properly functioning kidney from ... him guilty and suspended him for a period of 12 ... the French surgeon, Mr Blanchard’s conduct was inappropriate, unprofessional and ... ,He said that he had not read the patient's ...
... of the study, James Raftery, a professor health technology assessment ... decisions//. The National Institute for Health and Clinical Excellence (NICE) ... in 1999 and given the task of getting the best ... the NHS in England and Wales and recommends whether they ...
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
Cached Medicine News:Health News:Lower Literacy Puts Poor Health In Aging 2Health News:Lower Literacy Puts Poor Health In Aging 3
... need to add individual components for individual ... trauma indications. Made of an innovative composite ... fixators, only much lighter. This means it's ... more comfortable for the patient. ,Comes pre-assembled, ...
... osmolar ionic dimer. Each milliliter contains ... mg of ioxaglate sodium and 0.10 ... a stabilizer. The solution contains 3.48 ... and provides 32% (320 mg/mL) organically ...
... (iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. Indicated for a wide ... flexibility by providing a wide range of ...
... is a formulation of iopamidol in ... oral administration or, where necessary, by ... improvement in the radiological exploration of ... contrast media. Thanks to its low ...
Medicine Products: